Evidence map›Paper›PMID 32164321›Full record

ArticleMolecules (Basel, Switzerland)2020

Anticancer Activities of Newly Synthesized Chiral Macrocyclic Heptapeptide Candidates.

Mohamed H Abo-Ghalia, Gaber O Moustafa, Abd El-Galil E Amr, Ahmed M Naglah, Elsayed A Elsayed, Ahmed H Bakheit

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. CancerPPD2: an updated repository of anticancer peptides and proteins.Database : the journal of biological databases and curation · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. NDrug design, development and therapy · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed H Abo-GhaliaDepartment of Peptide Chemistry, National Research Centre, Dokki 12622, Cairo, Egypt.
Gaber O MoustafaDepartment of Peptide Chemistry, National Research Centre, Dokki 12622, Cairo, Egypt.ORCID 0000-0002-2489-8228
Abd El-Galil E AmrPharmaceutical Chemistry Department, Drug Exploration & Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-1338-706X
Ahmed M NaglahDepartment of Peptide Chemistry, National Research Centre, Dokki 12622, Cairo, Egypt.ORCID 0000-0003-4377-5239
Elsayed A ElsayedBioproducts Research Chair, Zoology Department, Faculty of Science, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-4774-4600
Ahmed H BakheitDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-0445-1357

Funding

King Saud University Researchers Supporting Project (No. RSP-2019/66
6 · The paper itself

Abstract

As important cancer therapeutic agents, macrocyclic peptides have recently drawn great attention, mainly because they are synthetically accessible and have lower toxicity towards normal cells. In the present work, we synthesized newly macrocyclic pyridoheptapeptide derivatives. The synthesized derivatives were characterized using standard chemical and spectroscopic analytical techniques, and their anticancer activities against human breast and hepatocellular cancer cells were investigated. Results showed that compounds 1a and 1b were the most effective against hepatocellular (HepG2) and breast (MCF-7) cancer cell lines, respectively.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell Line, TumorDrug Screening Assays, AntitumorFemaleHep G2 CellsHumansLiver NeoplasmsMacrocyclic CompoundsMCF-7 CellsMolecular Docking SimulationPeptide FragmentsStructure-Activity RelationshipAntineoplastic AgentsMacrocyclic CompoundsPeptide Fragments3,5-tetrapeptidopyridineamino acidsin vitro anticancer activitymacrocyclic heptapeptides

Identifiers

PMID32164321
PMCPMC7179445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.